Male, n (%)

177 (64.8)

Race, n (%)

White

Black

Asian

Not reported

260 (95.2)

9 (3.3)

3 (1.1)

1 (0.4)

Age at ipilimumab initiation, median years (range)

64 (26 - 91)

Primary site, n (%)

Cutaneous

Uveal

Mucosal

Other

241 (88.3)

12 (4.4)

5 (1.8)

15 (5.5)

Stage at advanced melanoma diagnosis, n (%)

Stage III (M0)

Stage IV (M1)

M1a

M1b

M1c

33 (12.1)

240 (87.9)

30 (11.0)

57 (20.9)

153 (56.0)

Brain metastases at advanced melanoma diagnosis, n (%)

33 (12.1)

ECOG PS at advanced melanoma diagnosis, n (%)

0

1

≥2

Unknown

104 (38.1)

116 (42.5)

19 (7.0)

34 (12.5)